L3VLUP
ProSign in

LLY · JNJ in the 13F filings

Two to four stocks side by side among the 95 tracked managers: who lists them, how that has moved, who bought and sold in a quarter, and which managers hold more than one.

LLYJNJ
Quarter
Q2 2026Q1 2026Q4 2025Q3 2025Q2 2025Q1 2025Q4 2024Q3 2024Q2 2024Q1 2024Q4 2023

Holders over time

Tracked managers listing each stock every quarter, at least, or their combined reported value. A gap is a quarter in which no tracked manager listed it. Click a quarter to compare there.
  • LLY
  • JNJ
0204060202120222023202420252026
Holders and value by quarter
QuarterLLYJNJ
Q3 202033 holders, $14.1bn30 holders, $26.2bn
Q4 202029 holders, $17.3bn32 holders, $26.6bn
Q1 202124 holders, $23.0bn31 holders, $25.3bn
Q2 202124 holders, $27.8bn37 holders, $25.6bn
Q3 202131 holders, $29.9bn40 holders, $24.1bn
Q4 202131 holders, $34.7bn33 holders, $25.2bn
Q1 202224 holders, $35.3bn35 holders, $28.2bn
Q2 202233 holders, $42.7bn33 holders, $26.9bn
Q3 202231 holders, $43.4bn36 holders, $25.4bn
Q4 202231 holders, $46.6bn35 holders, $27.6bn
Q1 202333 holders, $44.3bn42 holders, $24.5bn
Q2 202337 holders, $59.6bn38 holders, $25.0bn
Q3 202344 holders, $67.6bn37 holders, $18.9bn
Q4 202345 holders, $73.6bn31 holders, $19.0bn
Q1 202441 holders, $95.3bn32 holders, $19.7bn
Q2 202443 holders, $110bn35 holders, $20.4bn
Q3 202445 holders, $107bn28 holders, $22.3bn
Q4 202446 holders, $93.9bn37 holders, $20.4bn
Q1 202542 holders, $98.4bn32 holders, $20.5bn
Q2 202543 holders, $93.2bn31 holders, $18.4bn
Q3 202539 holders, $86.7bn32 holders, $23.7bn
Q4 202541 holders, $123bn29 holders, $27.8bn
Q1 202639 holders, $106bn34 holders, $35.6bn
Q2 202644 holders, $132bn33 holders, $39.1bn
LLY

Eli Lilly & Co

Holders
43
Reported value
$93.2bn
Buyers
25
Sellers
22

Breadth +3 among 95 comparable managers.

Pharmaceuticals and biotechnologyHealthcare: biopharma and medtech · L3VLUPPharmaceutical preparations
JNJ

Johnson & Johnson

Holders
31
Reported value
$18.4bn
Buyers
15
Sellers
16

Breadth -1 among 95 comparable managers.

Pharmaceuticals and biotechnologyHealthcare: biopharma and medtech · L3VLUPPharmaceutical preparations

Who holds both, Q2 2025

Among the 50 tracked managers listing any of them. "Only" is about listed positions: a manager may hold the other below its listed range.

Only LLY (19)

Artisan Partners LP, Balyasny Asset Management LLC, Capital World Investors, Citadel Advisors LLC, Coatue Management LLC, ExodusPoint Capital Management LP, Freestone Grove Partners LP, Harris Associates LP, Holocene Advisors LP, Hudson Bay Capital Management LP, Maverick Capital Ltd, Moore Capital Management LP, Polen Capital Management LLC, Rokos Capital Management LLP, Schonfeld Strategic Advisors LLC, Squarepoint Ops LLC, Tiger Global Management LLC, Viking Global Investors LP, Walleye Capital LLC

Only JNJ (7)

Arrowstreet Capital LP, Bridgewater Associates LP, Caxton Associates LLP, Markel Group Inc, Renaissance Technologies LLC, Verition Fund Management LLC, Winton Group Ltd

How much of the picture this is

A 13F is a manager’s long US-listed equity book at a quarter end, filed up to 45 days later. Buyers and sellers count comparable managers (those that filed both quarters) by shares, so a rise in value with no rise in shares is the price. Large books are listed to their largest positions. These are 95 tracked managers, not the institutional market.

Back to the 13F Explorer →